Nomic Bio

Nomic Bio is a biotechnology company based in Montreal, Quebec, with additional facilities in Boston, Massachusetts.

Founded in 2017, the company specializes in protein profiling and proteomics technology, aiming to make the human proteome as accessible and routine as the human genome. Nomic Bio focuses on revolutionizing drug discovery, diagnostics, and biomedical research through high-throughput, quantitative, and cost-effective protein data. The company's flagship technology is the nELISA® platform, a next-generation immunoassay system that allows for massive multiplexing and full quantification of proteins. Nomic Bio offers a range of services, including high-throughput protein profiling, immune secretome analysis, and custom protein panel development, catering to clients in pharmaceuticals, biotechnology, academia, and diagnostics. With over 25 million proteins profiled and more than 400,000 samples processed, Nomic Bio is committed to advancing the field of proteomics and supporting breakthroughs in various areas of biomedical research.